New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2013
09:02 EDTACTGAcacia reaches settlement with Mallinckrodt over Exalgo
Actavis announced that it has reached a settlement with Mallinckrodt on outstanding patent litigation related to Actavis' generic version of the 32 mg dosage strength of Mallinckrodt's Exalgo tablets. In January of 2012, Actavis and Mallinckrodt previously settled litigation involving the 8 mg, 12 mg and 16 mg dosage strengths of the product. Under terms of the settlement agreement, Mallinckrodt has granted Actavis a royalty-free license to U.S. patents relating to Exalgo to sell Actavis' 32 mg product starting on May 15, 2014. Other details of the settlement were not disclosed.
News For ACTG From The Last 14 Days
Check below for free stories on ACTG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 24, 2014
16:03 EDTACTGAcacia Research reports Q2 adjusted EPS 16c, may not compare consensus 6c
Subscribe for More Information
06:02 EDTACTGAcacia Research signs patent license agreement with Pregis and others
Subscribe for More Information
July 22, 2014
06:01 EDTACTGAcacia Research subsidiary enters into license agreement with Tecnotree OYJ
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use